Halozyme Therapeutics, Inc.

  • Health Care
  • Biotechnology: Biological Products (No Diagnostic Substances)
  • www.halozyme.com
  • Earnings Score
  • Moat Score
  • Safety Score
  • Market Cap $6.14B
  • PE 16
  • Debt $1.50B
  • Cash $154.32M
  • EV $7.49B
  • FCF $392.71M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$392.47M
EBIT$480.09M
ROE87%
ROA23%
FCF$392.71M
Equity$452.70M
Growth Stability100%
PE15.64
PEG0.47
PB13.56
P/FCF15.63
P/S6.48
Price/Cash0.03
Debt/Equity3.32
Debt/FCF3.83
Net Margins43%
Gross Margins82%
Op. Margins51%
Earnings CAGR11%
Sales Growth YoY34%
Sales Growth QoQ25%
Sales CAGR25%
FCF CAGR7%
Equity CAGR19%
Earnings Stability0.19
Earnings Growth YoY67%
Earnings Growth QoQ47%
Earnings CAGR 5Y33%
Sales CAGR 5Y46%
FCF CAGR 5Y43%
Equity CAGR 5Y22%
Earnings CAGR 3Y33%
Sales CAGR 3Y33%
FCF CAGR 3Y19%
Equity CAGR 3Y12%
Market Cap$6.14B
Revenue$947.36M
Assets$2.12B
Total Debt$1.50B
Cash$154.32M
Shares Outstanding126.85M
EV7.49B
Earnings Score10%
Moat Score98%
Safety Score79%
Final Score62%
Working Capital1.02B
Current Ratio10.36
Gross Profit$777.70M
Shares Growth 3y-4%
Equity Growth QoQ56%
Equity Growth YoY82%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

SEC Filings

Direct access to Halozyme Therapeutics, Inc. (HALO) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Halozyme Therapeutics, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Halozyme Therapeutics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 11%
Stability 19%
loading chart...

Halozyme Therapeutics, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Halozyme Therapeutics, Inc..

= $6.3B
012345678910TV
fcf$393M$419M$448M$478M$510M$545M$582M$621M$663M$708M$756M$7.6B
DCF$381M$370M$359M$348M$338M$328M$319M$309M$300M$291M$2.9B
Value$6.3B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins-91%-24%-70%20%-53%-37%48%91%31%34%43%
ROA--15%-32%16%-16%-12%25%25%15%20%23%
ROE--75%317%30%-32%-79%85%204%119%336%87%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF--1.82-4.462.13-4.05-5.5816.193.316.64.093.83
Debt over Equity1.211.67-7.341.360.885.445.6859.1418.23.32
Growth Stability--------100%100%100%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth-79%9%116%-52%29%37%66%49%26%46%
Earnings YoY growth--53%220%-161%-228%-10%-279%212%-50%39%33%
Equity YoY growth-4%-176%-742%19%-63%65%30%-14%-51%22%
FCF YoY growth--19%36%-348%-141%65%-159%463%-21%59%43%